Akari Therapeutics, Plc
AKTX
$1.12
-$0.03-2.61%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 9.71M | 10.71M | 10.24M | 11.35M | 12.20M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.23M | 17.69M | 18.49M | 19.14M | 18.20M |
| Operating Income | -15.23M | -17.69M | -18.49M | -19.14M | -18.20M |
| Income Before Tax | -17.93M | -19.79M | -20.16M | -20.13M | -16.58M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -17.93 | -19.79 | -20.16 | -20.13 | -16.58 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -17.93M | -19.79M | -20.16M | -20.13M | -16.58M |
| EBIT | -15.23M | -17.69M | -18.49M | -19.14M | -18.20M |
| EBITDA | -15.22M | -17.68M | -18.47M | -19.13M | -18.19M |
| EPS Basic | -2.74K | -4.12K | -5.62K | -6.28K | -6.25K |
| Normalized Basic EPS | -0.65 | -1.08 | -1.57 | -1.84 | -1.95 |
| EPS Diluted | -2.74K | -4.12K | -5.62K | -6.28K | -6.25K |
| Normalized Diluted EPS | -0.65 | -1.08 | -1.57 | -1.84 | -1.95 |
| Average Basic Shares Outstanding | 68.31M | 47.75M | 32.74M | 25.60M | 21.24M |
| Average Diluted Shares Outstanding | 34.00K | 23.70K | 16.10K | 12.60K | 10.40K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |